Managed Access Programs for LNP023, Iptacopan
Latest Information Update: 09 Feb 2024
At a glance
- Drugs Iptacopan (Primary)
- Indications Membranoproliferative glomerulonephritis
- Focus Expanded access; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 07 Feb 2022 New trial record